
Red yeast rice impact: Kobayashi Pharmaceutical records nearly US$25m losses in Q1
Kobayashi Pharmaceutical reported an “extraordinary loss” of nearly US$25m (JPY$3.86bn) in its Q1 results due to the recall of its contaminated red yeast rice products, raw materials, and compensation of medical expenses.


